| For: | Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, Patel H, Elquza E, McBride A. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol 2019; 11(10): 866-876 [PMID: 31662825 DOI: 10.4251/wjgo.v11.i10.866] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v11/i10/866.htm |
| Number | Citing Articles |
| 1 |
Tarinee Rungjirajittranon, Weerapat Owattanapanich, Yingyong Chinthammitr, Theera Ruchutrakool, Bundarika Suwanawiboon. Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis. Thrombosis Journal 2022; 20(1) doi: 10.1186/s12959-022-00399-7
|
| 2 |
Shinji Rho, Chris Wang, Seyed Hamed Hosseini Dehkordi, James J. Sears, Z. Ian Hu. Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications. American Heart Journal Plus: Cardiology Research and Practice 2023; 27 doi: 10.1016/j.ahjo.2023.100283
|
| 3 |
Damon E. Houghton, Danielle T. Vlazny, Ana I. Casanegra, Nichole Brunton, David A. Froehling, Ryan A. Meverden, David O. Hodge, Lisa G. Peterson, Robert D. McBane, Waldemar E. Wysokinski. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. Mayo Clinic Proceedings 2021; 96(11) doi: 10.1016/j.mayocp.2021.04.026
|
| 4 |
Tirath Patel, Taha Nadeem, Usman Shahbaz, Fatima Tanveer, Muneeb Ahsan, Usman Saeed, Abdullah Ahmed, Vinesh Kumar, Syed M Ibne Ali Jaffari, Mohammad U Zaman, Satesh Kumar, Mahima Khatri, Giustino Varrassi, Prasanthi Vanga. Comparative Efficacy of Direct Oral Anticoagulants and Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism: A Systematic Review and Meta-Analysis. Cureus 2023; doi: 10.7759/cureus.41071
|
| 5 |
Mercedes Salgado, Elena Brozos-Vázquez, Begoña Campos, Paula González-Villarroel, María Eva Pérez, María Lidia Vázquez-Tuñas, David Arias. Venous Thromboembolism In Cancer Patients: “From Evidence to Care”. Clinical and Applied Thrombosis/Hemostasis 2022; 28 doi: 10.1177/10760296221098717
|
| 6 |
Maryam R. Hussain, Faisal S. Ali, Dhiran Verghese, Phyo Thazin Myint, Mubashir Ahmed, Zimu Gong, Yasmin Gerais, Mahrukh Siddiqui, Jenny J. Lin, Kevin Troy. Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies. Critical Reviews in Oncology/Hematology 2022; 169 doi: 10.1016/j.critrevonc.2021.103526
|
| 7 |
Victoria R Nachar, Allison J Schepers. Clinical controversies in the treatment of cancer-associated venous thromboembolism. Journal of Oncology Pharmacy Practice 2021; 27(4) doi: 10.1177/1078155220984371
|
| 8 |
Jie Ren, Pingli Li. Direct oral anticoagulants compared to low molecular weight heparin for the treatment of venous thromboembolism among individuals with gastrointestinal cancer: an updated meta-analysis. Thrombosis Journal 2025; 23(1) doi: 10.1186/s12959-025-00789-7
|
| 9 |
Apixaban vs Rivaroxaban: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal 2026; 1(1) doi: 10.62487/saimsarae6ee9492
|
| 10 |
Brijesh Patel, Fawaz Alenezi, Vipul Bhanderi, Asha Ricciuti, Najam Gohar, Muhammad Moseeb Ali Hashim, Khadija Naeem, Muhammad Usman Arshad, Saba Aliha, Aman Ullah, Muhammad Arham, Areej Dar, Maliha Khalid, Yusra Junaid, Faizan Ahmed, Faseeh Haider. Direct oral anticoagulants <i>vs</i> low-molecular-weight heparins for cancer-associated thromboembolism. World Journal of Clinical Cases 2026; 14(17): 118087 doi: 10.12998/wjcc.v14.i17.118087
Abstract(35) |
Core Tip(29) |
Full Article(HTML)(103)
|
Full Article (PDF)-5320K(11)
|
Full Article with Cover (PDF)-5632K(8)
|
Full Article (XML)-195K(8)
|
Audio-1471K(3)
|
Peer-Review Report-233K(14)
|
Answering Reviewers-196K(13)
|
Supplementary Material-1587K(15)
|
Times Cited (0)
|
Total Visits (182)
|
Open
|
| 11 |
Wei Kang, Bowie P. Y. Lam, Rinko Tsz Lam Lau, Silvia T. H. Li, Kangrui Wu, Yue Wei, Yu Yang, Kyung Jin Lee, Caige Huang, Vincent K. C. Yan, Hei Hang Edmund Yiu, Shing Fung Lee, Aya El Helali, Victor H. F. Lee, Stephen L. Chan, Rina Y. M. Hui, Ka On Lam, Esther W. Chan. Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis. Drug Safety 2026; doi: 10.1007/s40264-026-01684-4
|
| 12 |
William J. Chapin, Preeti Sudheendra, Luis Goity, Deepak Sudheendra. Epidemiology, Prevention, Diagnosis, and Management of Venous Thromboembolism in Gastrointestinal Cancers. Digestive Disease Interventions 2020; 4(03) doi: 10.1055/s-0040-1716738
|
| 13 |
Mouhand F. H. Mohamed, Mohamad Nabil ElShafei, Mohamed Badie Ahmed, Lina O. Abdalla, Israa Ahmed, Abdel-Naser Elzouki, Mohammed ibn-mas’ud Danjuma. The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis 2021; 27 doi: 10.1177/1076029620940046
|
| 14 |
Maryam F Baloch, Adedimeji V Adepoju, Vaibhavkumar Falki, Mohsin Hajjaj, Tatiana Habet, Karina Habet, Amtul Mahrosh, Sumana Kundu, Janvi Kataria, Midhun Mathew, Tugba Saka, Mohammed Al-Tawil. Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis. Cureus 2023; doi: 10.7759/cureus.43447
|
| 15 |
A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Side Effects of Drugs Annual 2020; 42 doi: 10.1016/bs.seda.2020.08.011
|